Canaan XI L.P. - 01 Jun 2021 Form 4 Insider Report for Day One Biopharmaceuticals, Inc. (DAWN)

Role
10%+ Owner
Signature
Canaan XI L.P., By: Canaan Partners XI LLC, its general partner, By: /s/ Nancy Levenson, Attorney-in-Fact
Issuer symbol
DAWN
Transactions as of
01 Jun 2021
Net transactions value
+$208,000
Form type
4
Filing time
02 Jun 2021, 17:12:19 UTC
Previous filing
26 May 2021
Next filing
14 Sep 2021
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction DAWN Common Stock Conversion of derivative security +7,328,497 +226% 10,574,366 01 Jun 2021 Direct F1, F2
transaction DAWN Common Stock Conversion of derivative security +148,279 +1.4% 10,722,645 01 Jun 2021 Direct F2, F3
transaction DAWN Common Stock Purchase $208,000 +13,000 +0.12% $16.00 10,735,645 01 Jun 2021 Direct F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction DAWN Series A Preferred Stock Conversion of derivative security -7,328,497 -100% 0 01 Jun 2021 Common Stock 7,328,497 Direct F1, F2
transaction DAWN Series B Preferred Stock Conversion of derivative security -148,279 -100% 0 01 Jun 2021 Common Stock 148,279 Direct F2, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Each share of the Issuer's Series A Preferred Stock, which had no expiration date, automatically converted into one share of the Issuer's Common Stock at the close of the Issuer's initial public offering, for no additional consideration.
F2 These shares are held directly by Canaan XI L.P. (the "Canaan Fund"). The sole general partner of the Canaan Fund is Canaan Partners XI LLC ("Canaan XI", and together with the Canaan Fund, the "Canaan Entities"), and may be deemed to have sole voting, investment and dispositive power with respect to the shares held by the Canaan Fund. Investment and voting decisions with respect to the shares held by the Canaan Fund are made by the managers of Canaan XI, collectively. Canaan XI disclaims Section 16 beneficial ownership of the securities held by the Canaan Fund, except to the extent of its pecuniary interest therein, if any.
F3 Each share of the Issuer's Series B Preferred Stock, which had no expiration date, automatically converted into one share of the Issuer's Common Stock at the close of the Issuer's initial public offering, for no additional consideration.

Remarks:

Exhibit 24 - Power of Attorney (incorporated by reference to the Power of Attorney filed as Exhibit 24 to the Form 3 filed by the Reporting Persons on May 26, 2021)